Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walid Gharib

Cardiovascular Disease Morgantown, WV Medical Doctor

NPI 1063655264 CMS profile 229963

1 Medical Center Drive, Morgantown, WV 26506

Open in the dashboard

General payments

$6,060

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Walid Gharib of Morgantown, WV is reported in the CMS Open Payments database as having received $6,060 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $346 9
2024 General $167 7
2023 General $772 38
2022 General $1,335 69
2021 General $2,001 63
2020 General $294 21
2019 General $1,145 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walid Gharib
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Walid Gharib were reported at $346. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Walid Gharib Cardiovascular Disease median Middle half National median
2019 $1,145 $450 $127–$1,392 $163
2020 $294 $242 $77–$751 $114
2021 $2,001 $335 $101–$1,037 $132
2022 $1,335 $395 $121–$1,211 $149
2023 $772 $443 $136–$1,283 $160
2024 $167 $450 $136–$1,323 $164
2025 $346 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Terumo Medical Corporation $1,270 12 payments
  2. Pfizer Inc. $661 41 payments
  3. AstraZeneca Pharmaceuticals LP $585 34 payments
  4. Janssen Pharmaceuticals, Inc $518 36 payments
  5. Amgen Inc. $344 20 payments
  6. Novartis Pharmaceuticals Corporation $281 18 payments
  7. Actelion Pharmaceuticals US, Inc. $273 8 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $247 17 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $234 23 payments
  10. Stryker Corporation $200 2 payments
  11. Other $1,446 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,806 258 payments
  2. Travel and Lodging $1,040 4 payments
  3. Education $214 4 payments
Products named General payments · program years 2019–2025
  1. NAVICROSS $1,136 5 payments
  2. ELIQUIS $526 35 payments
  3. XARELTO $518 36 payments
  4. BRILINTA $411 28 payments
  5. VYNDAQEL $383 25 payments
  6. Repatha $344 20 payments
  7. JARDIANCE $247 17 payments
  8. LifeVest $234 23 payments
  9. OPSUMIT $210 7 payments
  10. ENTRESTO $198 13 payments
  11. Other $2,680 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

119

Median for Cardiology: 2,533

Drug cost

$665

Median for Cardiology: $485,213

Branded share of claims

22.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 44 $227
Clopidogrel Clopidogrel Bisulfate Brand 27 $211
Rosuvastatin Calcium Generic 25 $122
Atorvastatin Calcium Generic 12 $76
Amlodipine Besylate Generic 11 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$184,054

Medicare's payments for the services billed

Medicare patients

3,768

Average age 74

Services billed

8,627

1,990 women, 1,778 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 44%
Diabetes 40%
Atrial fibrillation 34%
Heart failure 33%
COPD 30%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record